Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 2/2004

01.01.2004 | Case Report

Thyroid hormone resistance and enlargement of the sella turcica during pregnancy

verfasst von: Charalambos Siristatidis, George Mastorakos, Nikolaos Vitoratos, Odysseas Gregoriou, Helen Iakovidou, Emmanuel Salamalekis, George Creatsas

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Case report.

A 26-year-old pregnant woman was admitted to our institution running her 30 weeks of gestation. The patient had a past history of total thyroidectomy cause of a thyroid papillary carcinoma and presented with increased supraphysiological TSH levels under 250 µg T4, while slightly hyperthyroid, from the clinical point of view. Partial resistance to thyroid replacement therapy or TSH-secreting tumour was evoked. Pituitary MRI revealed a pituitary enlargement without excluding a pituitary adenoma. To avoid further stress on pituitary a caesarean section was performed at 38 weeks of gestation. MRI 7 months later was normal, while the patient remained under high doses of T4 replacement therapy and TSH was found at the upper limits of normalcy, while T3, T4 and FTI were above normalcy.

Conclusion.

We conclude that, in the absence of thyroid gland, high TSH levels due to thyroid hormone resistance could be erroneously attributed to a pituitary TSH secreting tumour, when associated with a pregnancy-related pituitary enlargement.
Literatur
1.
Zurück zum Zitat Akiyoshi F, Okamura K, Fujikawa M, Sato K, Yoshinari M, Mizokami T, Hattori K, Juwayama Y, Fujishima M (1996) Difficulty in differentiating thyrotropin secreting pituitary microadenoma from pituitary-selective thyroid hormone resistance accompanied by pituitary incidentaloma. Thyroid 6:619–625CrossRefPubMed Akiyoshi F, Okamura K, Fujikawa M, Sato K, Yoshinari M, Mizokami T, Hattori K, Juwayama Y, Fujishima M (1996) Difficulty in differentiating thyrotropin secreting pituitary microadenoma from pituitary-selective thyroid hormone resistance accompanied by pituitary incidentaloma. Thyroid 6:619–625CrossRefPubMed
2.
Zurück zum Zitat Asteria C, Rjanayagam O, Collingwood TN, Persani L, Romoli R, Mannavola D, Zamprerini P, Buzi F, Ciralli F, Chatterjee VK, Beck P (1999) Prenatal diagnosis of thyroid hormone resistance. J Clin Endocrinol Metab 84:405–410CrossRefPubMed Asteria C, Rjanayagam O, Collingwood TN, Persani L, Romoli R, Mannavola D, Zamprerini P, Buzi F, Ciralli F, Chatterjee VK, Beck P (1999) Prenatal diagnosis of thyroid hormone resistance. J Clin Endocrinol Metab 84:405–410CrossRefPubMed
3.
Zurück zum Zitat Caron P, Gerbeau C, Pradayrol L, Simonetta C, Bayard F (1996) Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). J Endocrinol Metab 81:1164–1168 Caron P, Gerbeau C, Pradayrol L, Simonetta C, Bayard F (1996) Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). J Endocrinol Metab 81:1164–1168
4.
Zurück zum Zitat Fantz CR, Dagogo-Jack S, Ladenson JH, Gronowski AM (1999) Thyroid function during pregnancy. Clin Chem 45:2250–2258CrossRefPubMed Fantz CR, Dagogo-Jack S, Ladenson JH, Gronowski AM (1999) Thyroid function during pregnancy. Clin Chem 45:2250–2258CrossRefPubMed
5.
Zurück zum Zitat Garcia MM, Kapcala LP (1995) Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 18:450–455CrossRefPubMed Garcia MM, Kapcala LP (1995) Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 18:450–455CrossRefPubMed
6.
7.
Zurück zum Zitat Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ (1988) Pituitary gland growth during normal pregnancy: an in vivo study using MRI. Am J Med 85:217–220CrossRefPubMed Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ (1988) Pituitary gland growth during normal pregnancy: an in vivo study using MRI. Am J Med 85:217–220CrossRefPubMed
8.
9.
Zurück zum Zitat Jan M, Destrieux C (2000) Pituitary disorders in pregnancy. Neurochirurgie 46:88–94PubMed Jan M, Destrieux C (2000) Pituitary disorders in pregnancy. Neurochirurgie 46:88–94PubMed
10.
Zurück zum Zitat Mestman J Jr (1999) Diagnosis and management of maternal and fetal thyroid disorders. Curr Opin Obstet Gynecol 11:167–175CrossRefPubMed Mestman J Jr (1999) Diagnosis and management of maternal and fetal thyroid disorders. Curr Opin Obstet Gynecol 11:167–175CrossRefPubMed
11.
Zurück zum Zitat Persani L, Borgato S, Romoli R, Asteria C, Pizzocaro A, Beck-Pecco (1998) Changes in the degree of sialylation of carbohydrate chains modify the biological properties of circulating thyrotropin isoforms in various physiological and pathological states. J Clin Endocrinol Metab 83:2486–2492PubMed Persani L, Borgato S, Romoli R, Asteria C, Pizzocaro A, Beck-Pecco (1998) Changes in the degree of sialylation of carbohydrate chains modify the biological properties of circulating thyrotropin isoforms in various physiological and pathological states. J Clin Endocrinol Metab 83:2486–2492PubMed
12.
Zurück zum Zitat Preger D, Braunstein GD (1995) Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 24:1–14CrossRef Preger D, Braunstein GD (1995) Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 24:1–14CrossRef
13.
Zurück zum Zitat Sarkissian G, Dce A, Mesmacque A, Bony-Trifunovic H, Malezet-Desmoulius C, Torresani J, Margotat A (1999) A novel resistance to thyroid hormone associated with a new mutation (T329 N) in the thyroid hormone receptor beta gene. Thyroid 9:165–171CrossRefPubMed Sarkissian G, Dce A, Mesmacque A, Bony-Trifunovic H, Malezet-Desmoulius C, Torresani J, Margotat A (1999) A novel resistance to thyroid hormone associated with a new mutation (T329 N) in the thyroid hormone receptor beta gene. Thyroid 9:165–171CrossRefPubMed
14.
Zurück zum Zitat Spitz JM, Sheinfeld M, Glasser B, Hirsch HJ (1984) Hyperthyroidism due to inappropriate TSH secretion with associated hyperprolactinaemia a case report and review of the literature. Postgrad Med J 60:328–335CrossRefPubMedPubMedCentral Spitz JM, Sheinfeld M, Glasser B, Hirsch HJ (1984) Hyperthyroidism due to inappropriate TSH secretion with associated hyperprolactinaemia a case report and review of the literature. Postgrad Med J 60:328–335CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Stockigt JR, Barlow JW (1985) The diagnostic challenge of euthyroid hyperthyroxinemia. Aust N Z J Med 15:277–284CrossRefPubMed Stockigt JR, Barlow JW (1985) The diagnostic challenge of euthyroid hyperthyroxinemia. Aust N Z J Med 15:277–284CrossRefPubMed
16.
Zurück zum Zitat Wajchenberg BL, Tsanaclis AM, Marino Junior R (1984) TSH-containing pituitary adenoma associated with primary hypothyroidism manifested by amenorrhoea and galactorrhoea. Acta Endocrinol (Copenh) 106:61–66 Wajchenberg BL, Tsanaclis AM, Marino Junior R (1984) TSH-containing pituitary adenoma associated with primary hypothyroidism manifested by amenorrhoea and galactorrhoea. Acta Endocrinol (Copenh) 106:61–66
Metadaten
Titel
Thyroid hormone resistance and enlargement of the sella turcica during pregnancy
verfasst von
Charalambos Siristatidis
George Mastorakos
Nikolaos Vitoratos
Odysseas Gregoriou
Helen Iakovidou
Emmanuel Salamalekis
George Creatsas
Publikationsdatum
01.01.2004
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 2/2004
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-002-0455-8

Weitere Artikel der Ausgabe 2/2004

Archives of Gynecology and Obstetrics 2/2004 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.